enzalutamide,talazoparib
astellas,pfizer
['talapro,2', 'prostate', 'brca', 'talazo', 'crpc', 'talapro-2']
#asco2023 continuing with first results of the ph3 talapro-2 trial in 1st line hrr+ mcrpc #prostatecancer impressive results with talazoparib+enza beyond brca1/2 ie.palb2, cdk12 etc significant delay in chemo, psa pfs +conclusions 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/ywWAdZmBWt